Melatonin derivative 6a as a PARP-1 inhibitor for the treatment of Parkinson's disease.

Authors:
Ma QW; Han RT; Wu ZJ; Zhou JJ; Chen MT and 3 more

Journal:
Front Pharmacol

Publication Year: 2024

DOI:
10.3389/fphar.2024.1363212

PMCID:
PMC10927953

PMID:
38476326

View on PubMed View on PMC View Publisher

Journal Information

Journal Title: Front Pharmacol

Detailed journal information not available.

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score

3/6

50.0% Transparent

Transparency Indicators

Click on green indicators to view evidence text

Core Indicators

Data Sharing

Code Sharing

COI Disclosure

Evidence found in paper:

"Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

Funding Disclosure

Evidence found in paper:

"The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was financially supported by NSFC (22101213) and the Hong Kong–Macao Joint Research and Development Fund of Wuyi University (2019WGALH12)."

Protocol Registration

Open Access

Paper is freely available to read

Additional Indicators

Replication

Novelty Statement

Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025